Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, novembre 19
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Abbott Laboratories
ABT
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$104.48
-0.23
-0.22%
In chiusura: Nov 18, 4:00 PM EST
$104.46
-0.02
-0.02%
Post-mercato: 6:39 PM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Abbott Laboratories Financials
Abbott Laboratories (ABT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today
SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
Piero Cingari
Abbott CEO Rules Out Selling $8.5 Billion Nutrition Business: 'No Interest'
Abbott (ABT) to spin off its $8.5B nutrition arm, makers of Ensure & Similac, by end of 2027. Stock dips following Q3 results.
Vandana Singh
Meta, Tesla On Deck Wednesday As AI Spending, Auto Demand Face Test
Meta Platforms and Tesla headline Wednesday’s reports, with investors focused on whether AI investment can keep driving growth while Tesla’s core auto business weakens. Philip Morris International, Thermo Fisher
Benzinga Insights
PRO
Abbott Laboratories Narrows FY2026 Adj EPS Guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 Est
Abbott Laboratories (NYSE:ABT) narrows FY2026 Adj EPS guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 analyst estimate..
Benzinga Newsdesk
PRO
Abbott Laboratories Sees Q4 Adj EPS $1.62-$1.67 vs $1.64 Est
Abbott Laboratories (NYSE:ABT) is looking for Q4 Adj EPS of $1.62-$1.67 vs $1.64 analyst estimate..
Benzinga Newsdesk
PRO
Abbott Laboratories Q3 Adj. EPS $1.42, Inline, Sales $13.013B Beat $12.998B Estimate
Abbott Laboratories (NYSE:ABT) reported quarterly earnings of $1.42 per share which met the analyst consensus estimate. This is a 9.23 percent increase over earnings of $1.30 per share from the same period last year.
Benzinga Newsdesk